Skip to content

A Study Comparing the effect of Nagakeshara and Surpunnaga for change in symptoms of Abnormal Uterine Bleeding in 60 women participants.

A Randomised Comparative Clinical Study To Evaluate The Efficacy Of Nagakeshara(Messua Ferrae Linn. ) And Its Market Substitute Surpunnaga(Ochrocarpus Longifolius Benth and Hook) In The Management Of Asragdara Wsr To Abnormal Uterine Bleeding. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/081612
Enrollment
60
Registered
2025-03-04
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified

Interventions

None listed

Sponsors

National Institute Of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects gave the complaint of Asragdara with any two of the following features for 2 consecutive cycles. Heavy menstrual bleeding (amount Greater than 80ml) (Amount more than 80 ml will be assessed by pictorial blood loss assessment chart scoring more than 100 points.) Prolonged menstrual bleeding Greater than 7 days. Inter menstrual bleeding with/without heavy flow or Frequent menstrual cycle less than 24days. Features different from normal menstrual blood, pain, burning sensation, body ache.

Exclusion criteria

Exclusion criteria: Patients with chronic of systemic illness (Congestive cardiac failure, Hypertension, cirrhosis of liver, Tuberculosis endometritis, severe anemia, chronic renal disease, Insulin dependent diabetes mellitus etc.). Patients using Intrauterine contraceptive device or oral contraceptive pills (latrogenic). Patients with uterine and pelvic pathology (Fibroid size Greater than 2 cm, endometriosis, adenomyosis, polyp, high grade cervical erosion, endometrial thickness Greater than 20mm etc.). Benign and malignant growth. Thyroid dysfunction (endocrinal disorders). Patients having bleeding due to abortion, ectopic pregnancy, during puerperium. Patients taking Anti-coagulation therapy and having hematological disorders (Leukemia, Thrombocytopenic Purpura). Postmenopausal bleeding. Sexually transmitted infections/Genital tract infections.

Design outcomes

Primary

MeasureTime frame
Change in symptoms of AsragdaraTimepoint: Change in the symptoms of Asragdara from baseline to 2 months of period.

Secondary

MeasureTime frame
Changes in PBLAC scoring system.Timepoint: Changes in PBLAC scoring system from baseline to 2 months of period.

Countries

India

Contacts

Public ContactDisha Parmar

National Institute Of Ayurved

sumitnathani24@gmail.com7665809886

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026